Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,485
Change Today 0.00 / 0.00%
Volume 0.0
KMDA On Other Exchanges
Tel Aviv
As of 10:24 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/12/14 - $2,596
52 Week Low
11/25/14 - $1,160
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company’s lung disease products include Glassia used in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for regular treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies infection; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. The company also provides critical care products, such as Heparin Lock Flush to maintain patency of indwelling IV catheter; Heparin sodium injection to treat thrombo-embolic disorders; Kamacaine 0.5% used as anesthesia or analgesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Albumin for maintenance of circulating blood volume. In addition, it offers Transferrin for diagnostic assays and cell cultures; and coagulation factors, including Factor VIII, Factor IX, and Human Transferrin. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary diseases, graft-versus-host diseases, and transplantations. It has collaboration partnerships with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

302 Employees
Last Reported Date: 04/28/15
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $207.0K
Co-Founder, Deputy Executive Chairman and Pre...
Total Annual Compensation: $455.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $234.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $242.0K
Vice President of Research and Development
Total Annual Compensation: $212.0K
Compensation as of Fiscal Year 2014.

kamada ltd (KMDA) Key Developments

Kamada Announces New Collaboration with Baxter's Unit for Lung-Transplant Treatment Study

Kamada Ltd. reported it has entered into a collaboration agreement for its phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection with Baxter International's Baxalta International subsidiary. Under the terms of the agreement, Baxalta will collaborate in the development and funding of the study, which is expected to begin in the first half of 2016 in Israel. Financial terms of the agreement weren't disclosed.

Kamada Ltd. Proposes Amendments to Articles of Association

Kamada Ltd. announced the AGM to be held on June 30, 2015 to approve certain amendments to Articles of Association.

Kamada Ltd., Annual General Meeting, Jun 30, 2015

Kamada Ltd., Annual General Meeting, Jun 30, 2015., at 15:00 Israel Standard Time. Location: 7 Sapir Street, Kiryat Weizmann Science Park. Agenda: To reelect six directors to serve as members of Board of Directors until next AGM of shareholders; to approve certain amendments to Articles of Association, Compensation Policy and certain agreements with current office holders relating to exculpation of office holders; to approve the terms of engagement of Mr. David Tsur as Active Deputy Chairman, effective as of July 1, 2105 and Mr. Amir London as Chief Executive Officer, effective as of July 1, 2105; to approve the grant of options to directors other than the external directors (within the meaning of the Israeli Companies Law, 5759-1999) and Mr. David Tsur; to ratify and approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accountants for the year ending December 31, 2015 and for such additional period until next annual general meeting; and to review and discuss consolidated financial statements for the year ended December 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,485.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.27 EUR -0.58
View Industry Companies

Industry Analysis


Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at